Genus PLC (LSE:GNS) — Market Cap & Net Worth
Market Cap & Net Worth: Genus PLC (GNS)
Genus PLC (LSE:GNS) has a market capitalization of $19.04 Million (GBX156.47 Billion) as of May 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #25174 globally and #254 in its home market, demonstrating a -6.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genus PLC's stock price GBX2356.00 by its total outstanding shares 66412699 (66.41 Million). Analyse how efficiently does Genus PLC generate cash to see how efficiently the company converts income to cash.
Genus PLC Market Cap History: 2015 to 2026
Genus PLC's market capitalization history from 2015 to 2026. Data shows growth from $11.37 Million to $19.04 Million (5.69% CAGR).
Index Memberships
Genus PLC is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$62.11 Billion | 0.03% | #183 of 573 |
|
FTSE 350
FTLC
|
$61.53 Billion | 0.03% | #179 of 350 |
|
FTSE 250
FTMC
|
$8.75 Billion | 0.22% | #89 of 250 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.55 Billion | 0.54% | #4 of 6 |
Weight: Genus PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genus PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genus PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Genus PLC's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.09x
Genus PLC's market cap is 1.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $13.30 Million | $388.30 Million | $49.30 Million | 0.03x | 0.27x |
| 2017 | $18.96 Million | $459.10 Million | $32.80 Million | 0.04x | 0.58x |
| 2018 | $16.27 Million | $470.30 Million | $42.70 Million | 0.03x | 0.38x |
| 2019 | $24.32 Million | $488.50 Million | $7.80 Million | 0.05x | 3.12x |
| 2020 | $32.36 Million | $551.40 Million | $35.30 Million | 0.06x | 0.92x |
| 2021 | $38.31 Million | $574.30 Million | $47.30 Million | 0.07x | 0.81x |
| 2022 | $23.39 Million | $593.40 Million | $40.90 Million | 0.04x | 0.57x |
| 2023 | $17.24 Million | $689.70 Million | $33.30 Million | 0.03x | 0.52x |
| 2024 | $12.52 Million | $668.80 Million | $7.90 Million | 0.02x | 1.59x |
| 2025 | $20.97 Million | $672.80 Million | $19.30 Million | 0.03x | 1.09x |
Competitor Companies of GNS by Market Capitalization
Companies near Genus PLC in the global market cap rankings as of May 3, 2026.
Key companies related to Genus PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Genus PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Genus PLC's market cap moved from $11.37 Million to $ 19.04 Million, with a yearly change of 5.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX19.04 Million | -9.21% |
| 2025 | GBX20.97 Million | +67.42% |
| 2024 | GBX12.52 Million | -27.36% |
| 2023 | GBX17.24 Million | -26.28% |
| 2022 | GBX23.39 Million | -38.95% |
| 2021 | GBX38.31 Million | +18.39% |
| 2020 | GBX32.36 Million | +33.08% |
| 2019 | GBX24.32 Million | +49.48% |
| 2018 | GBX16.27 Million | -14.20% |
| 2017 | GBX18.96 Million | +42.56% |
| 2016 | GBX13.30 Million | +16.99% |
| 2015 | GBX11.37 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Genus PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.04 Million USD |
| MoneyControl | $19.04 Million USD |
| MarketWatch | $19.04 Million USD |
| marketcap.company | $19.04 Million USD |
| Reuters | $19.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more